JY028 (bevacizumab biosimilar) / Beijing Eastern Biotech  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
JY028 (bevacizumab biosimilar) / Beijing Eastern Biotech
ChiCTR1900022369: A Phase I Clinical Trial for JY028 (single-dose; vitreous injection) on Safety , tolerability, pharmacokinetics (PK) and pharmacodynamics for Patients with wet Age-related macular degeneration

Not yet recruiting
1
24
 
intravitreal injection JY028 0.625mg ;intravitreal injection JY028 1.25mg ;intravitreal injection JY028 2mg ;intravitreal injection JY028 2.5mg
Beijing Tongren Hospital, CMU; Beijing Tongren Hospital, CMU, Self-raised funds
Age-related macular degeneration
 
 
NCT03725566: JY028 Single Vitreous Injection in a Phase 1 Clinical Trial in nAMD Patients

Unknown status
1
24
RoW
Experimental, intravitreous injection
Beijing Tongren Hospital
Macular Degeneration
05/20
05/20
ChiCTR2000035350: A randomized, double-blind, parallel controlled phase I trial comparing the pharmacokinetics of recombinant humanized Monoclonal antibody against VEGF (JY028) injection with Anvertin in healthy subjects

Not yet recruiting
1
92
 
A single dose of 3mg/kg ;A single dose of 3mg/kg
Shanghai Public Health Clinical Center; Shanghai Public Health Clinical Center, sponsor
Healthy male subjects
 
 

Download Options